Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

885 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A. Giannini G, et al. Among authors: rinaldi c. Breast Cancer Res Treat. 2006 Nov;100(1):83-91. doi: 10.1007/s10549-006-9225-9. Epub 2006 May 9. Breast Cancer Res Treat. 2006. PMID: 16847550
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Buffone A, Capalbo C, Ricevuto E, Sidoni T, Ottini L, Falchetti M, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. Buffone A, et al. Among authors: rinaldi c. Breast Cancer Res Treat. 2007 Dec;106(2):289-96. doi: 10.1007/s10549-007-9499-6. Epub 2007 Feb 28. Breast Cancer Res Treat. 2007. PMID: 17333342
Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.
Coppa A, Nicolussi A, D'Inzeo S, Capalbo C, Belardinilli F, Colicchia V, Petroni M, Zani M, Ferraro S, Rinaldi C, Buffone A, Bartolazzi A, Screpanti I, Ottini L, Giannini G. Coppa A, et al. Among authors: rinaldi c. Cancer Med. 2018 Jan;7(1):46-55. doi: 10.1002/cam4.1251. Epub 2017 Dec 22. Cancer Med. 2018. PMID: 29271107 Free PMC article.
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
Capalbo C, Ricevuto E, Vestri A, Ristori E, Sidoni T, Buffone O, Adamo B, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. Capalbo C, et al. Among authors: rinaldi c. Ann Oncol. 2006 Jun;17 Suppl 7:vii34-40. doi: 10.1093/annonc/mdl947. Ann Oncol. 2006. PMID: 16760289 Free article.
Human MRE11 is inactivated in mismatch repair-deficient cancers.
Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, Ottini L, Crescenzi M, Martinotti S, Bignami M, Frati L, Screpanti I, Gulino A. Giannini G, et al. Among authors: rinaldi c. EMBO Rep. 2002 Mar;3(3):248-54. doi: 10.1093/embo-reports/kvf044. Epub 2002 Feb 15. EMBO Rep. 2002. PMID: 11850399 Free PMC article.
Molecular mechanism of HMGA1 deregulation in human neuroblastoma.
Giannini G, Cerignoli F, Mellone M, Massimi I, Ambrosi C, Rinaldi C, Gulino A. Giannini G, et al. Among authors: rinaldi c. Cancer Lett. 2005 Oct 18;228(1-2):97-104. doi: 10.1016/j.canlet.2005.01.045. Cancer Lett. 2005. PMID: 15923078 Review.
885 results